Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

July 22nd 2024

An expert in the field provides insights into current clinical trials investigating the efficacy of combined BCL-2 inhibitor and BTK inhibitor therapies.

Fixed-Duration Venetoclax-Based Combos Maintain Benefit in Frontline CLL

July 17th 2024

Moritz Fürstenau, MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

July 16th 2024

John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.

Perspectives on Shared Decision-Making in the Treatment of CLL

July 16th 2024

Bita Fakhri, MD, MPH, discusses the importance of patient involvement in the shared decision-making process to individualize treatment and improve outcomes.

Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL

July 15th 2024

Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach.

Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D

July 15th 2024

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy

July 15th 2024

A chronic lymphocytic leukemia expert examines patient criteria for first-line doublet therapy (venetoclax plus BTK inhibitor) versus triplet therapy, while also addressing findings from the CAPTIVATE trial.

Dr Phillips on Evolving Treatment Strategies in Both MCL and CLL

July 11th 2024

Tycel Phillips, MD, discusses the evolution of treatment strategies for patients with either chronic lymphocytic leukemia or mantle cell lymphoma.

Dr Fürstenau on the Efficacy of Frontline Venetoclax-Based Combinations in CLL

July 10th 2024

Moritz Fürstenau MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

July 9th 2024

Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.

Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

July 9th 2024

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.

Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

July 8th 2024

The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.

Frontline BTKi Selection

July 8th 2024

Key opinion leaders examine the use of continuous Bruton's tyrosine kinase inhibitor therapy in front-line treatment, strategies for sequencing therapies, and the potential incorporation of obinutuzumab into treatment regimens.

First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL

July 3rd 2024

Orelabrutinib plus FCG led to undetectable MRD in all patients with untreated chronic lymphocytic leukemia who completed 12 cycles of therapy

Dr Dorritie on Unanswered Questions Regarding Upfront Treatment Selection in CLL

July 3rd 2024

Kathleen A. Dorritie, MD, discusses unmet needs regarding upfront treatment selection in chronic lymphocytic leukemia.

Implications of Real-World Data in the 1L Treatment of High-Risk CLL

July 3rd 2024

Catherine C. Coombs, MD, discusses the value of real-world data in informing the treatment of patients with chronic lymphocytic leukemia.

Navigating Continuous BTKi Therapy for CLL in the 1L Setting

July 3rd 2024

John N. Allan, MD, describes how he selects patients for first-line treatment with continuous BTK inhibitor therapy, referencing data from the RESONATE-2, ELEVATE-TN, and SEQUOIA studies.

Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL

June 27th 2024

Leading chronic lymphocytic leukemia specialists explore strategies for selecting initial treatments, weighing the merits of fixed-duration versus continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy for newly diagnosed patients.

Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024

June 27th 2024

Key opinion leaders are introduced and present a concise overview of the topics to be addressed.

Dr Ghia on Long-Term Efficacy With Acalabrutinib Monotherapy in CLL

June 26th 2024

Paolo Ghia, MD, PhD, discusses long-term follow-up data from a pooled analysis evaluating the efficacy of acalabrutinib monotherapy in CLL.